DEVELOP ASSAY TO QUANT PLAT-DNA ADDUCTS & PREDICT RESPONSE TO CHEMOTHERA

$58,316P41FY2009RRNIH

University Of Calif-Lawrnc Lvrmr Nat Lab, Livermore CA

Investigators

Linked publications & trials

Paper 38339135 Paper 32029633 Paper 30381944 Paper 30152692 Paper 30135423 Paper 29654160 Paper 28437852 Paper 28428366 Paper 28148721 Paper 27936622 Paper 27903751 Paper 27640312 Paper 27213172 Paper 27065506 Paper 26799320 Paper 26223300 Paper 25929573 Paper 25395738 Paper 24860204 Paper 24628688 Paper 24623226 Paper 24074980 Paper 23922751 Paper 23746839 Paper 23674270 Paper 23467295 Paper 23456194 Paper 23441119 Paper 23394702 Paper 23361949 Paper 23359559 Paper 23199207 Paper 23077194 Paper 22955965 Paper 22892282 Paper 22871115 Paper 22865590 Paper 22711420 Paper 22517541 Paper 22399585 Paper 22197725 Paper 22004428 Paper 21947005 Paper 21775555 Paper 21715470 Paper 21708019 Paper 21622940 Paper 21452856 Paper 21427733 Paper 21208756 Paper 21128223 Paper 21083256 Paper 21083255 Paper 21083245 Paper 21062031 Paper 21048058 Paper 21028869 Paper 20976120 Paper 20853316 Paper 20833264 Paper 20676755 Paper 20660280 Paper 20660050 Paper 20454606 Paper 20368758 Paper 20349979 Paper 20335033 Paper 20163100 Paper 19997880 Paper 19965905 Paper 19952359 Paper 19799643 Paper 19548665 Paper 19535418 Paper 19430162 Paper 19399913 Paper 19342590 Paper 19276345 Paper 18785762 Paper 18785761 Paper 18763242 Paper 18632763 Paper 18533685 Paper 18454136 Paper 18025045 Paper 17638912 Paper 17592118 Paper 17344499 Paper 17279779 Paper 17158427 Paper 17079477 Paper 17052995 Paper 16901981 Paper 16696564 Paper 16585531 Paper 16401518 Paper 16047147 Paper 16009139 Paper 15990134 Paper 15982874

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. AMS will be applied to measuring the platinum-DNA adducts for drug pharmacokinetics. In spite of the importance of platinum-based anticancer drugs (cisplatin, carboplatin and oxaliplatin), their mechanisms of action, repair of damaged DNA and pharmacokinetics are unclear because of the detection limit of conventional methods (conventional methods have failed in quantifying Pt-DNA adducts with cells incubated with a pharmacological dose of the anticancer agent, which is the reason we need the sensitivity of AMS). In order to address these important issues, 14C-labeled carboplatin and oxaliplatin will be administered to E. coli, human cells, and bladder cancer patients, which may overcome the previous detection limits even at sub-pharmacological doses. The goals are to use AMS to elucidate their in vivo mechanism of action, to correlate Pt-DNA adduct level with cell death using a variety of human cancer cells, to determine the pharmacokinetics of the patients dosed with 14C-labeled carboplatin and oxaliplatin, and to ultimately correlate the phamacokinetic results to individual outcome (patient survival). Experimentally, after dosing a number of human cancer cells or cancer patients with radioactive platinum-based anticancer drugs, cell lysis and extracted platinated DNA will be measured by AMS. These 'real-time pharmacokinetics'will allow determination of which cancer patients will benefit from platinum treatment and which will be resistant to the drugs. Because of the high sensitivity, AMS is the very best technology for realizing these challenging goals.

View original record on NIH RePORTER →